Indication

As maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists

Medicine details

Medicine name:
indacaterol/mometasone furoate (Atectura Breezhaler)
SMC ID:
SMC2356
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Publication due date:
10 May 2021